Management of incomplete remission and treatment resistance in first-episode psychosis.

abstract：:Paracetamol (acetaminophen) is one of the over-the-counter analgesics that is used frequently for the self-management of some of the common disorders. There seems to be two types of relations between paracetamol and asthma - paracetamol intolerance leading to bronchospasm in analgesic-induced asthmatics; and the relat...

journal_title：Expert opinion on pharmacotherapy

authors： Karakaya G,Kalyoncu AF

更新日期：2003-01-01 00:00:00

abstract：:Osteoporosis is a severe condition, associated with significant disability as a result of fragility fractures and increased mortality. Oral bisphosphonates effectively reduce the risk of osteoporotic fracture and are generally well tolerated. Unfortunately, patient outcomes are often compromised by suboptimal therapeu...

journal_title：Expert opinion on pharmacotherapy

authors： Reginster JY

更新日期：2005-10-01 00:00:00

abstract：INTRODUCTION:Treatment options for hair disorders are generally very limited. These options are even more limited in children due to the lack of trials and clinical research. Moreover, physicians are sometimes scared to treat children with drugs without safety data, especially because most hair disorders are benign. A...

journal_title：Expert opinion on pharmacotherapy

authors： Iorizzo M,Oranje AP

更新日期：2016-09-01 00:00:00

abstract：BACKGROUND:Radiodermatitis in its acute and chronic presentations represents a set of specific adverse effects resulting from ionizing radiations. Skin-field cancerization is another condition associated to or independent of clinically recognizable radiodermatitis. This condition leads to the risk of later occurrence o...

journal_title：Expert opinion on pharmacotherapy

authors： Piérard GE,Piérard-Franchimont C,Paquet P,Quatresooz P

更新日期：2009-04-01 00:00:00

abstract：:Correct education of the patient is one of the most important aspects in the treatment of Tourette's syndrome. Pharmacotherapy is often unsatisfactory and therefore should be limited to those patients who are significantly impaired. Therapy must be individualised and the most troublesome symptom should be targeted fir...

journal_title：Expert opinion on pharmacotherapy

authors： Müller-Vahl KR

更新日期：2002-07-01 00:00:00

abstract：:Sertraline (Zoloft, Pfizer Inc.) is a selective serotonin re-uptake inhibitor (SSRI) which has been approved by the US FDA for the treatment of premenstrual dysphoric disorder (PMDD). PMDD is a severe form of premenstrual syndrome (PMS) which affects at least 5 - 8% of women of reproductive age. It is characterised by...

journal_title：Expert opinion on pharmacotherapy

authors： Halbreich U,Kahn LS

更新日期：2003-11-01 00:00:00

abstract：BACKGROUND:There is at present no cure for multiple sclerosis (MS), and existing therapies are designed primarily to prevent lesion formation, decrease the rate and severity of relapses and delay the resulting disability by reducing levels of inflammation. OBJECTIVE:The aim of this review was to assess the treatment o...

journal_title：Expert opinion on pharmacotherapy

authors： Hartung HP

更新日期：2009-02-01 00:00:00

abstract：BACKGROUND:The safety and efficacy of sodium glucose co-transporter 2 inhibitors in non-obese compared with obese patients with type 2 diabetes mellitus is unknown. METHODS:We conducted post hoc analyses of the results of a 52-week open-label study of Japanese type 2 diabetes mellitus patients treated with 100 or 200 ...

journal_title：Expert opinion on pharmacotherapy

authors： Inagaki N,Goda M,Yokota S,Maruyama N,Iijima H

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Prescription omega-3-acid ethyl esters (P-OM3) have been used as adjunctive therapy to statin drugs in patients with mixed hyperlipidemia. OBJECTIVE:To assess the effect of concomitant administration of 4 g P-OM3 on the steady-state pharmacokinetics of the maximum recommended daily dose of atorvastatin (80 ...

journal_title：Expert opinion on pharmacotherapy

authors： Di Spirito M,Morelli G,Doyle RT,Johnson J,McKenney J

更新日期：2008-12-01 00:00:00

abstract：:The administration of oral aspirin within 48 h and tissue plasminogen activator within 3 h of ischaemic stroke onset remain the only treatments that have been shown to have clinical benefit. There has been much excitement about neuroprotection over the last two decades, as it may minimise the harmful effects of ischae...

journal_title：Expert opinion on pharmacotherapy

authors： Ly JV,Zavala JA,Donnan GA

更新日期：2006-08-01 00:00:00

abstract：BACKGROUND:Alzheimer's disease is thought to be caused by increased formations of neurotoxic amyloid beta (A beta) peptides, which give rise to the hallmark amyloid plaques. Therefore, pharmacological agents that reduce A beta formation may be of therapeutic benefit. OBJECTIVE:This paper reviews the pharmacology and c...

journal_title：Expert opinion on pharmacotherapy

authors： Henley DB,May PC,Dean RA,Siemers ER

更新日期：2009-07-01 00:00:00

abstract：:One of the most significant advances of the last decade has been the development of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors. A large series of randomised, controlled clinical trials of these agents have shown a significant reduction in ischaemic events, not only in acute coronary syndrome patients, but...

journal_title：Expert opinion on pharmacotherapy

authors： Anne G,Gruberg L

更新日期：2004-02-01 00:00:00

abstract：INTRODUCTION:Brimonidine tartrate is a commonly used eyedrop for short- and long-term lowering of intraocular pressure. Its use has been popularized due to its effects on aqueous suppression and uveoscleral outflow, as well as the suggestion of neuroprotection. Although available with alternative preservative vehicles,...

journal_title：Expert opinion on pharmacotherapy

authors： Oh DJ,Chen JL,Vajaranant TS,Dikopf MS

更新日期：2019-01-01 00:00:00

abstract：:Insulin glulisine (Apidra, Sanofi-Aventis), a new and recently approved rapid-acting insulin analogue, mimics the pharmacokinetic and pharmacodynamic profiles of physiological human insulin, but has a rapid onset, peak effect at 1h, and a shorter duration of action (approximately 4 h). Its rapid-action properties are ...

journal_title：Expert opinion on pharmacotherapy

authors： Garg SK,Ellis SL,Ulrich H

更新日期：2005-04-01 00:00:00

abstract：INTRODUCTION:Epilepsy is a serious and common chronic neurological disease with an urgent need for novel treatment options, because 30% of all epilepsy patients do not respond to currently available drugs. Retigabine/Ezogabine (RTG) is a third-generation antiepileptic drug (AED) with a novel mechanism of action. It enh...

journal_title：Expert opinion on pharmacotherapy

authors： Orhan G,Wuttke TV,Nies AT,Schwab M,Lerche H

更新日期：2012-08-01 00:00:00

abstract：:Ramipril is an angiotensin-converting enzyme inhibitor that has been extensively studied in randomised, controlled clinical trials in patients with cardiovascular diseases. Therapy with ramipril in patients with various cardiovascular disorders has demonstrated significant and clinically important reductions in cardio...

journal_title：Expert opinion on pharmacotherapy

authors： Rokoss MJ,Teo KK

更新日期：2005-09-01 00:00:00

abstract：PURPOSE:To assess ocular surface status and tolerability after switching glaucoma patients from dorzolamide/timolol to brinzolamide/timolol fixed combination (FC). METHODS:Six-month, multicenter, open-label, prospective study that switched 72 patients from dorzolamide/timolol to brinzolamide/timolol FC. Intraocular pr...

journal_title：Expert opinion on pharmacotherapy

authors： Rossi GC,Pasinetti GM,Sandolo F,Bordin M,Bianchi PE

更新日期：2011-11-01 00:00:00

abstract：:Lapatinib is a dual (ErbB-1 and ErB-2) receptor tyrosine kinase inhibitor (TKI) that was recently approved by the FDA for the treatment of advanced breast cancer. It shows synergy with trastuzumab, and has demonstrated clinical activity in trastuzumab-resistant tumour. This paper reviews the drug development of lapati...

journal_title：Expert opinion on pharmacotherapy

authors： Mukherjee A,Dhadda AS,Shehata M,Chan S

更新日期：2007-09-01 00:00:00

abstract：BACKGROUND:Treating HIV-infected children remains a challenge due to a lack of treatment options, appropriate drug formulations and, in countries with limited resources, insufficient access to diagnostic tests and treatment. OBJECTIVE:To summarize current data concerning new opportunities to improve the treatment of H...

journal_title：Expert opinion on pharmacotherapy

authors： Van der Linden D,Callens S,Brichard B,Colebunders R

更新日期：2009-08-01 00:00:00

abstract：:Glatiramer acetate (Copaxone, Teva Pharmaceuticals Ltd) is a collection of immunomodulatory, synthetic polypeptides indicated for the treatment of relapsing-remitting multiple sclerosis (RR MS). Preclinical and clinical studies provide an evolving understanding of the mechanisms by which glatiramer acetate exerts both...

journal_title：Expert opinion on pharmacotherapy

authors： Wolinsky JS

更新日期：2004-04-01 00:00:00

abstract：:Screening for sexually transmitted diseases is included in routine health care for several infectious agents in many western European countries. Current considerations on extensions of these programs include widespread screening strategies for Chlamydia trachomatis. In women, C. trachomatis infection may lead to seque...

journal_title：Expert opinion on pharmacotherapy

authors： Postma MJ,Welte R,Morré SA

更新日期：2002-10-01 00:00:00

abstract：INTRODUCTION:Much research has gone into developing medications that can be used to alleviate endometriosis-associated symptoms. In addition to already established medications, a new GnRH antagonist, elagolix, is in development. The novelty of this drug compared to other GnRH antagonists, is its nonpeptide structure, a...

journal_title：Expert opinion on pharmacotherapy

authors： Perricos A,Wenzl R

更新日期：2017-09-01 00:00:00

abstract：BACKGROUND:Tamoxifen is the established adjuvant treatment for postmenopausal women with hormone-sensitive breast cancer. OBJECTIVE:To determine whether the aromatase inhibitor anastrozole should replace tamoxifen as the adjuvant treatment in this cancer. METHODS:Two recent trials of anastrozole and tamoxifen as adju...

journal_title：Expert opinion on pharmacotherapy

authors： Doggrell SA

更新日期：2008-06-01 00:00:00

abstract：:There has been a significant increase in the number of cases of skin cancer diagnosed in the US in the past few years. Thus, it seems appropriate to review the available compounds that might be used in the chemoprevention of these lesions. This review focuses on the retinoids and details their results in clinical tria...

journal_title：Expert opinion on pharmacotherapy

authors： Niles RM

更新日期：2002-03-01 00:00:00

abstract：:Ribavirin is a very broad-spectrum virustatic antiviral agent, first synthesised in 1972. It is characterised by low toxicity apart from reversible anaemia, usually mild. Its multiple mechanisms of action mean that viral resistance rarely develops. It can be administered orally, intravenously, or via a nebuliser. It h...

journal_title：Expert opinion on pharmacotherapy

authors： Snell NJ

更新日期：2001-08-01 00:00:00

abstract：INTRODUCTION:Antifungal resistance is an emerging problem that increases morbidity and mortality in immunosuppressed pediatric patients, who suffer from invasive fungal diseases. Optimal pharmacological management is critical for the successful treatment of invasive fungal infections by resistant strains. AREAS COVERE...

journal_title：Expert opinion on pharmacotherapy

authors： Stergiopoulou T,Walsh TJ

更新日期：2015-02-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Most guidelines suggest that failure of oral antidiabetic drugs should be followed by the addition of a basal insulin with aggressive titration of the dose. In most countries, neutral protamine Hagedorn (NPH)-insulin, glargine and detemir are the only choices. Clinical trials show that the metab...

journal_title：Expert opinion on pharmacotherapy

authors： Jensen MG,Hansen M,Brock B,Rungby J

更新日期：2010-08-01 00:00:00

abstract：:The recently published results of the sequential treatment of postmenopausal osteoporotic women with subcutaneous abaloparatide (80 µg/day) (ABL) for 18 months followed by 6 months of oral alendronate (70 mg/week) (ALN) support the administration of an anti-resorptive agent after completion of a treatment course with ...

journal_title：Expert opinion on pharmacotherapy

authors： Reginster JY,Al Daghri N,Kaufman JM,Bruyère O

更新日期：2018-02-01 00:00:00

abstract：:Candesartan is a long-acting angiotensin receptor antagonist that is well absorbed from the gastrointestinal tract, with insurmountable receptor binding abilities. Recent studies have shown candesartan to be an effective therapy for heart failure patients, producing a significant reduction in mortality and morbidity. ...

journal_title：Expert opinion on pharmacotherapy

authors： McKelvie RS

更新日期：2006-10-01 00:00:00

abstract：BACKGROUND:This subgroup analysis of STELLA-LONG TERM interim data explored the long-term safety and efficacy of ipragliflozin in non-elderly vs. elderly Japanese type 2 diabetes mellitus (T2DM) patients. RESEARCH DESIGN AND METHODS:STELLA-LONG TERM is an ongoing 3-year prospective surveillance study of Japanese T2DM ...

journal_title：Expert opinion on pharmacotherapy

authors： Maegawa H,Tobe K,Tabuchi H,Nakamura I,Uno S

更新日期：2018-03-01 00:00:00